An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy

NCT01454531 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

199

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Rhinoconjunctivitis

Interventions

DRUG: AVANZ Phleum pratense

Sponsor

ALK-Abelló A/S